StockWatch
·
UNITED BREWERIES LTD. · Q2 FY-2027 · PREVIEW

Q2 FY27: Can UBL Sustain Margin Recovery Amid Monsoon Weakness?

The brewer faces its acid test in Q2—whether premiumisation and cost discipline can offset seasonal volume headwinds. JPMorgan has trimmed EBITDA forecasts 8%, but H2 FY27 recovery is signalled on track.

Q2 FY27 resultsUBLUNITED BREWERIES LTD.-$21 Oct 2026 · 3 min read

United Breweries reports Q2 FY27 (quarter ended 30 September 2026) on 27 October, when the board convenes to approve results. The quarter sits at a pivot: premiumisation is delivering double-digit growth, but seasonal monsoon weakness has hit overall volumes. The Street will parse whether cost discipline and the tax refund can cushion margin compression, or whether FY27's growth story is now a back-half play.

On-Plan Expectations

Revenue

~₹5,100–5,300 Cr

Modest seasonal softness from Q1's ₹5,919 Cr; monsoon offset by YoY growth vs Q2 FY26 (₹2,052 Cr, though note: Q2 FY26 was heavily impacted by severe weather).

EBITDA margin

~5–6%

Slight recovery from Q1's 4.77%, supported by steady input costs and improving return-bottle ratios. JPMorgan trimmed Q2 EBITDA forecasts by ~8%, signalling tighter year-on-year comparison.

Premium volume growth

~15–18%

Heineken Silver (+28% in Q1) and Kingfisher Ultra (+11%) continue momentum; expected to offset weakness in mainstream beer due to monsoon.

PAT (estimated)

~₹120–150 Cr

Lower than Q1's ₹166 Cr due to operating deleverage from volume pressures; other income (₹51 Cr in Q1 from tax matters) will be a wildcard.

A strong Q2 would show: volumes down less than 5% YoY (or flat), EBITDA margin above 5.5%, and management guidance for H2 FY27 at-plan or better (volume growth 6–7% for full year per JPMorgan). A weak Q2 would be: volumes down more than 5%, margin below 5%, and cautious H2 guidance amid persistent input cost inflation or slower monsoon recovery.

Street View: Mixed Signals, Consensus Bearish

Since Last Quarter: Filings & Corporate Actions

UBL has been active operationally and in resolving legacy tax matters:

Recent Events (Since Q1 FY27 Announcement, 4 August 2026)

5 Oct 2026

Event

Tax refund of ₹100.83 Cr received (AY 2013–14: ₹82.73 Cr, AY 2018–19: ₹18.10 Cr)

Impact

Positive: material cash inflow; will cushion Q2 profitability and de-risk tax uncertainty

29 Sep 2026

Event

Tax penalty demand of ₹54.8 Cr from NFAC (multiple assessment years)

Impact

Neutral: offset partially by recent refunds; part of ongoing legacy tax resolution

4 Sep 2026

Event

Tax litigation win: ₹21.92 Cr favourable order from High Court of Bombay (Aurangabad bench)

Impact

Positive: adds to refund momentum; high court validates UBL's tax position on service matter

1 Sep 2026

Event

New canning line commissioned at Ellora Brewery, Maharashtra (₹110 Cr investment, 4 MLPA capacity, Sept operational)

Impact

Positive: capex completion on track; capacity for growth; operational upside in Q3–Q4

25 Aug 2026

Event

Heineken Silver expansion to Kerala, Odisha, Madhya Pradesh (3 new states; was in 11 states post-Oct 9 push)

Impact

Positive: geographic diversification of premium brand; supports premiumisation thesis

17 Jul 2026

Event

Canning line commissioned at Nizam Brewery, Telangana (₹90 Cr investment, operational post-success validation)

Impact

Positive: capex completion; regional capacity boost; supports regional volume upside in H2

No promoter pledges, insider selling, or major corporate actions post-Q1. Ownership stable: FII 4.88% vs DII 17.78% (latest Q1 FY27 filing; FII marginally down from prior quarters). Tax resolution is the standout: ₹100.83 Cr inflow and high court wins reduce legacy uncertainty and support the bottom line—a one-time tailwind worth watching for timing in P&L impact.

FY27 Trajectory: On Track?

UBL guided for 6–7% volume growth in FY27 (per JPMorgan's post-Q1 read). Q1 delivered +10% revenue growth but -9.65% PAT decline, due to operating margin compression (EBITDA margin fell 170 bps to 9.2% on input cost stickiness). Q2 is a test: if monsoon impact is contained and margins stabilise, H2 should see sequential recovery as weather normalises and capex capacity ramps. If Q2 margins compress further, FY27 may need a 5–6% full-year volume growth rephrase, and target prices may reset downward. The Street is betting on the former; JPMorgan's H2 recovery call hinges on this Q2 read.

What to Watch on Result Day

Four metrics that will frame the narrative
  • 1 · Volume growth (overall and premium mix)

    Key: How much did monsoon hurt? Management will flag sell-out vs sell-in volatility. Premium volumes (Heineken Silver, Kingfisher Ultra) should show >15% growth. If overall volumes are down >5%, the recovery thesis stalls.

  • 2 · EBITDA margin and gross margin bridge

    The swing item: did input cost ratios improve (return-bottle, packaging)? EBITDA margin >5.5% would signal cost discipline; <5% would suggest inflation is outpacing pricing. Management commentary on input cost trajectory into Q3 is critical.

  • 3 · Tax refund and other income timing

    ₹100.83 Cr refund received Oct 5. Will UBL book it in Q2 or defer? Timing here creates significant P&L variance. If booked, PAT could beat estimates despite operating softness.

  • 4 · FY27 full-year guidance reaffirm or reset

    Management's read on H2 recovery (volume 6–7% growth, margin stabilisation). If they signal slower H2 or capex delays at Ellora/Nizam, street will reprice. A reaffirm with Q2 context builds confidence in JPMorgan's overweight case.

UBL's Q2 FY27 is a watershed: premiumisation is working (Heineken Silver +28%, Kingfisher Ultra +11%), capex completion at Nizam and Ellora de-risks capacity, and tax refunds are flowing (₹100.83 Cr). But monsoon hammered July–September volume—JPMorgan cut Q2 EBITDA forecasts by 8%—and input cost inflation persists, squeezing margins to ~5–6%. The stock is down 47.6% from highs, dividing the Street (consensus sell, but JPMorgan overweight at ₹2,050 target). Result day will hinge on three things: (1) how much did volumes really contract, (2) can margins hold above 5%, and (3) does management reaffirm H2 FY27 recovery on track? If yes to all three, the 14% JPMorgan upside case has legs. If not, the rerating cycle stalls.

Informational and educational content only. Not investment advice.